Advertisement

Psychopharmacologia

, Volume 44, Issue 3, pp 273–280 | Cite as

Clinical studies with dopamine-receptor stimulants

  • Burton Angrist
  • Hyacinth Thompson
  • Baron Shopsin
  • Samuel Gershon
Human Pharmacology

Abstract

Oral administration of ET-495 was found to cause worsening of psychiatric status in 4 out of 7 schizophrenic patients, and to induce a paranoid state and a syndrome of auditory hallucinosis in 2 non-schizophrenics. These observations were compatible with the hypothesized role of dopamine in schizophrenia. However, these psychotogenic effects were far less dramatic than those noted in other studies with amphetamine, methylphenidate or l-Dopa. Possible explanations for this differing psychotogenic potency of receptor stimulators versus presynaptic agonists are presented. Intravenous ET-495 and apomorphine did not show psychotogenic effects.

Key words

Schizophrenia Dopamine ET 495 Apomorphine Clinical studies 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anden, N. E., Corrodi, H., Fuxe, K.: Turnover studies using synthesis inhibition. In: Metabolism of amines in the brain, G. Hopper, ed., pp. 38–47. New York: Macmillan 1969Google Scholar
  2. Angrist, B. M., Gershon, S.: The phenomenology of experimentally-induced amphetamine psychosis: Preliminary observations. Biol. Psychiat. 2, 95–107 (1970)Google Scholar
  3. Angrist, B. M., Sathananthan, G. S., Gershon, S.: Behavioral effects of l-Dopa in schizophrenic patients. Psychopharmacologia (Berl.) 31, 1–12 (1973)Google Scholar
  4. Chase, T. N.: Clinical studies of dopaminergic mechanisms. In: Neuropsychopharmacology of monoamines and their regulatory enzymes, E. Usdin, ed., pp. 427–434. New York: Raven Press 1974Google Scholar
  5. Chase, T. N., Shoulson, I.: Dopaminergic mechanisms in patients with extrapyramidal disease. In: Advances in neurology, Vol. 9, D. B. Calne, T. N. Chase, and A. Barbeau, eds., pp. 359–366. New York: Raven Press 1975Google Scholar
  6. Connell, P. H.: Amphetamine psychosis, Maudsley Monographs, No. 5, Oxford: University Press 1958Google Scholar
  7. Corrodi, H., Fuxe, K., Ungerstedt, U.: Evidence for a new type of dopamine receptor stimulating agent. J. Pharm. Pharmacol. 23, 989–991 (1971)Google Scholar
  8. Costall, B., Naylor, R. J.: Is there a relationship between the involvement of extrapyramidal and mesolimbic brain areas with the cataleptic action of neuroleptic agents and their clinical effect? Psychopharmacologia (Berl.) 32, 161–170 (1973a)Google Scholar
  9. Costall, B., Naylor, R. J.: On the mode of action of apomorphine. Europ. J. Pharmacol. 21, 350–361 (1973b)Google Scholar
  10. Cotzias, G. C.: Levodopa, manganese and degenerations of the brain, harvey society lectures. Delivered 1972 under the auspices of the Harvey Society Series 68, pp. 115–147 New York: Academic Press 1974Google Scholar
  11. Creese, I.: Behavioral evidence of dopamine receptor stimulation by piribedil (ET-495) and its metabolite S 584. Europ. J. Pharmacol. 28, 55–58 (1974)Google Scholar
  12. Davis, J. M., Janowsky, D. S.: Amphetamine and methylphenidate psychosis. In: Frontiers in catecholamine research, pp. 977–981. London: Pergamon Press 1973Google Scholar
  13. Duby, S. E., Cotzias, G. C., Papavasiliou, P. S., Lawrence, W. H.: Injected apomorphine and orally administered levodopa in Parkinsonism. Arch. Neurol. (Chic.) 27, 474–480 (1972)Google Scholar
  14. Dunkley, B., Sanghvi, I., Friedman, E., Gershon, S.: Comparison of behavioral and cardiovascular effects of l-Dopa and 5-HTP in conscious dogs. Psychopharmacologia (Berl.) 26, 161–172 (1972)Google Scholar
  15. Ellinwood, E. H., Jr., Sudilowsky, A., Nelson, L.: Behavioral analysis of chronic amphetamine intoxication. Biol. Psychiat. 4, 215–230 (1972)Google Scholar
  16. Ernst, A. M.: Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats. Psychopharmacologia (Berl.) 10, 316–323 (1967)Google Scholar
  17. Everett, G. M., Borcherding, J. W.: l-Dopa: Effect on concentration of dopamine, norepinephrine, and serotonin in brains of mice. Science 168, 849–850 (1970)Google Scholar
  18. Friedman, E., Gershon, S.: l-Dopa: Centrally mediated emission of seminal fluid in male rats. Life Sci. 11, 435–440 (1972)Google Scholar
  19. Fuxe, K., Agnate, L. F., Corrodi, H., Everitt, B. J., Hokfelt, T., Lofström, J., Ungerstedt, U.: Action of dopamine receptor agonists in forebrain and hypothalamus: Rotational behavior, ovulation and dopamine turnover. In: Advances in neurology, Vol. 9, D. B. Calne, T. N. Chase, and A. Barbeau, eds., pp. 223–242. New York: Raven Press 1975Google Scholar
  20. Garrattini, S., Barreggi, S., Marc, V., Calderini, G., Marsella, P. L.: Effects of piribedil on noradrenaline and MOPEGSO4 levels in the rat brain. Europ. J. Pharmacol. 28, 214–216 (1974)Google Scholar
  21. Goldberg, L. I.: Comparison of putative dopamine receptors in blood vessels and the central nervous system. In: Advances in neurology, Vol. 9, D. B. Calne, T. N. Chase, and A. Barbeau, eds., pp. 53–56. New York: Raven Press 1975Google Scholar
  22. Goldstein, M., Battista, A. F., Ohmoto, T., Anagnoste, B., Fuxe, K.: Tremor and involuntary movements in monkeys: Effects of l-Dopa and of a dopamine receptor stimulating agent. Science 179, 816–817 (1973)Google Scholar
  23. Griffeth, J. J., Cavanaugh, J., Oates, J.: Psychosis induced by the administration of d-amphetamine to human volunteers. In: Psychotomimetic drugs, D. H. Efron, ed., pp. 287–294. New York: Raven Press 1970Google Scholar
  24. Janowsky, D. S., Davis J. M.: Dopamine, psychomotor stimulants and schizophrenia: Effects of methylphenidate and the stereoisomers of amphetamine in schizophrenics. In: Neuropsychopharmacology of monoamines and their regulatory enzymes, E. Usdin, ed., pp. 317–323. New York: Raven Press 1974Google Scholar
  25. Karobath, M., Diaz, J.-L., Huttunen, M. O.: The effect of l-Dopa on the concentrations of tryptophan, tyrosine, and serotonin in rat brain. Europ. J. Pharmacol. 4, 393–396 (1971)Google Scholar
  26. Leiberman, A., Le Brun, Y., Dinkar, B., Zolfaghari, M.: The use of a dopaminergic receptor stimulating agent (Piribedil, ET-495) in Parkinson's disease. In: Neuropsychopharmacology of monoamines and their regulatory enzymes, E. Usdin, ed., pp. 415–425. New York: Raven Press 1974Google Scholar
  27. Lewander, T.: Effect of chronic-treatment with central stimulants on brain monoamines and some behavioral and physiological functions in rats, guinea pigs and rabbits. In: Neuropsychopharmacology of monoamines and their regulatory enzymes, E. Usdin, ed., pp. 221–239. New York: Raven Press 1974Google Scholar
  28. Maj, J., Pawlowski, L.: The hypothermic effect of l-Dopa in the rat. Life Sci. 13, 141–149 (1973)Google Scholar
  29. Nymark, M.: Apomorphine provoked stereotypy in the dog. Psychopharmacologia (Berl.) 26, 361–368 (1972)Google Scholar
  30. Randrup, A., Munkvad, I.: Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacologia (Berl.) 11, 300–310 (1967).Google Scholar
  31. Rotrosen, J., Wallach, M. B., Angrist, B., Gershon, S.: Antagonism of apomorphine induced stereotypy and emesis in dogs by thioridazine, haloperidol, and pimozide. Psychopharmacologia (Berl.) 26, 185–194 (1972)Google Scholar
  32. Sathananthan, G., Angrist, B. M., Gershon, S.: Response threshold to l-Dopa in psychiatric patients. Biol. Psychiat. 7, 139–146 (1973)Google Scholar
  33. Schwab, R. S., Amador, L. V., Lettvin, J. Y.: Apomorphine in Parkinson's disease. Trans. Amer. neurol. Ass. 76, 251–263 (1951)Google Scholar
  34. Snyder, S. H.: Amphetamine psychosis: A “model” schizophrenia mediated by catecholamines. Amer. J. Psychiat. 130, 61–67 (1973)Google Scholar
  35. Strian, F., Michler, E., Benkert, O.: Tremor inhibition in Parkinson syndrome after apomorphine administration under l-Dopa and decarboxylase inhibitor basic therapy. Pharmakopsychiat. 5, 198–205 (1972)Google Scholar
  36. Ungerstedt, U.: Postsynaptic supersensitivity after 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine system. Acta physiol scand., Suppl. 367, 69–93 (1971)Google Scholar
  37. Van Beek, M. C., Timmerman, H.: Some benzhydryl derivatives as central dopamine receptor stimulating agents. J. Pharm. Pharmacol. 26, 57–58 (1974)Google Scholar
  38. Walters, J., Bunney, B. S., Roth, R. H.: Piribedil and apomorphine: Pre- and postsynaptic effects on dopamine synthesis and neuronal activity. In: Advances in neurology, Vol. 9, D. B. Calne, T. N. Chase, and A. Barbeau, eds., pp. 273–284. New York: Raven Press 1975Google Scholar
  39. Willner, J. H., Samach, M., Angrist, B. M., Wallach, M. B., Gershon, S.: Drug induced stereotyped behavior and its antagonism in dogs. Commun. Behav. Biol. 5, 135–141 (1970)Google Scholar

Copyright information

© Springer-Verlag 1975

Authors and Affiliations

  • Burton Angrist
    • 1
  • Hyacinth Thompson
    • 1
  • Baron Shopsin
    • 1
  • Samuel Gershon
    • 1
  1. 1.Neuropsychopharmacology Research Unit, Department of PsychiatryNew York University Medical CenterNew York

Personalised recommendations